Skip to main content

Table 2 Modeling on risk of progression on ibrutinib

From: Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Variable PP versus CR/PR SD versus CR/PR
RR 95% CI p value RR 95% CI p value
Age at diagnosis 1.02 0.96–1.08 0.61 0.99 0.96–1.03 0.65
Gender
 Male Referent      
 Female 1.05 0.34–3.22 0.93 1.22 0.54–2.78 0.63
BMI
  < 30 Referent      
  ≥ 30 0.95 0.22–4.04 0.94 1.14 0.43–3.01 0.79
ECOG PS at diagnosis
 0 Referent      
 1 0.39 0.10–1.46 0.16 0.66 0.25–1.73 0.40
  ≥ 2 1.04 0.09–11.61 0.97 1.28 0.19–8.75 0.80
MZL subtype
 NMZL Referent      
 SMZL 1.32 0.31–5.63 0.71 0.78 0.27–2.19 0.63
 EMZL 1.40 0.38–5.20 0.61 0.69 0.26–1.79 0.44
Stage at diagnosis
 1–2 Referent      
 3–4 1.18 0.23–6.06 0.84 0.92 0.31–2.75 0.88
B symptoms at diagnosis
 No Referent      
 Yes 0.58 0.15–2.30 0.44 0.65 0.24–1.76 0.40
LDH higher than institutional baseline
 No Referent      
 Yes 1.37 0.35–5.28 0.65 0.84 0.30–2.33 0.73
Monoclonal protein at diagnosis
 No Referent      
 Yes 3.46 0.64–18.84 0.15 0.41 0.14–1.19 0.10
BM involvement at diagnosis
 No Referent      
 Yes 0.60 0.16–2.15 0.43 0.85 0.33–2.20 0.74
TP53 mutation/17p deletion
 No       
 Yes 0.76 0.08–7.25 0.81 0.81 0.15–4.48 0.81
Complex cytogenetics
 No       
 Yes 4.63 0.81–26.35 0.08 1.63 0.32–8.21 0.55
Primary refractory disease*
 No       
 Yes 3.77 1.15–12.33 0.03 1.72 0.66–4.47 0.26
Line of ibrutinib therapy
 Second line       
 Third line 0.82 0.23–2.90 0.76 0.65 0.24–1.70 0.38
 Fourth line and beyond 1.21 0.26–5.54 0.81 1.76 0.62–5.04 0.29
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, MZL marginal zone lymphoma, LDH lactate dehydrogenase, BM bone marrow
  2. *Primary refractory disease: defined as progression of disease at the end of induction therapy or within 6 months of treatment completion